TREATMENT OF LUPUS ANTICOAGULANT IN PREGNANCY

患有“狼疮抗凝剂”的患者， 与磷脂循环抗体相关的， 增加静脉和动脉血栓形成的风险。 怀孕 具有这种抗体的妇女胎儿丢失的风险很高， 可能是由于螺旋小动脉水平的血栓形成 或位于胎盘的母体底部。 影响妇女 反复流产的患者都接受了治疗 在随后的免疫抑制妊娠中， 抗凝 有风险的怀孕允许比较 乳酸免疫抑制的有效性或 抗凝在预防血栓形成超过有限的 一个特定的治疗终点。 我们计划 免疫抑制的前瞻性随机协作试验 与抗凝治疗相比， 并发症，并将比较胎儿结局和母体 这两种方案的安全性。 一种特异性免疫测定法将 用于测量母体血清中抗 定制免疫抑制疗法，以维持正常的 血清抗体水平

Patients with the "lupus anticoagulant", a clotting abnormality associated with circulating antibodies to phospholipids, are at increased risk for both venous and arterial thromboses. Pregnant women with such antibodies are at high risk for fetal loss, presumably due to thrombosis at the level of the spiral arterioles or within the maternal floor of the placenta. Affected women with repeated pregnancy loss have been treated prophyllactically in subsequent pregnancies with immunosuppression and anticoagulation. Pregnancies at risk permit comparison of the effectiveness of prophyllactic immunosuppression or anticoagulation in the prevention of thromboses over a limited period of time with a specific treatment end point. We plan a prospective, randomized collaborative trial of immunosuppression versus anticoagulation for pregnant patients at risk for this complication and will compare both fetal outcome and maternal safety of these two regimens. A specific immunoassay will be used for measurement of maternal serum levels of antibody to tailor immunosuppressive therapies for the maintenance of normal serum antibody levels.